Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-RGX-314 Gene Therapy in nAMD (ATMOSPHERE)
NCT04704921Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2020
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 3, randomised trial of surabgene lomparvovec in neovascular age-related macular degeneration (NVAMD) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Best Corrected Visual Acuity at 54 weeks and Incidence of ocular Adverse Events and any Serious Adverse Events at 50 weeks. Started Dec 2020; status: active, not recruiting.
02
Drugs
surabgene lomparvovec
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04704921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04704921.